To ask His Majesty's Government, following their response to the consultation on the extent of the impact on inward investment of higher payments under the statutory scheme to control the costs of branded medicines, what assessment they have made of the sensitivity analysis used to assess that impact; and whether they are proposing changes to that analysis.
Answered on
9 February 2023
The Department has received materials from pharmaceutical industry Trade Associations and from individual companies about the impact of changes to the voluntary and statutory schemes for branded medicines prices.
These include responses to the assessments made by the Department in the draft impact assessment that accompanies our recent consultation on increased rates in the statutory scheme. We will be considering this evidence over the coming weeks and will publish our response alongside the final impact assessment.